

H₂S in the Vasculature: Controversy of Mechanisms in Physiology, Pathology and Beyond

Nishijima Y¹ and Beyer AM^{1,2*}¹Department of Medicine and Cardiovascular Center, Medical College of Wisconsin, Wisconsin, USA²Department of Physiology Medical College of Wisconsin, Wisconsin, USA

Abstract

Hydrogen sulfide (H₂S) is an endogenously gaseous messenger with a number of physiological effects. Pharmacological and genetic models point toward an important role for this vasodilator gas in the regulation of vascular tone, cardiac response to ischemia/reperfusion injury, and inflammation among others. Understanding the complex interaction of H₂S with basic cellular signaling and its impact on endothelial and smooth muscle physiology may provide insights into the early stages of developing vascular inflammation and atherosclerosis or related vascular pathologies. The underlying mechanism of action is not completely understood. Recent evidence suggests a key role of H₂S in protecting mitochondria against oxidative damage, regulation of ion channels and modulation of eNOS activity. This review will focus on the key role of H₂S in the regulation of vascular function including free radical production and its physiological role in health and disease.

Keywords: Hydrogen sulfide; Gasotransmitter; Atherosclerosis; Oxyhemoglobin; EDHF

Abbreviations: ↑: increase/activate; ↓: decrease/inactivate/inhibit; AA: arachidonic acid; cAMP: Cyclic Adenosine Monophosphate; ADRF: Adipocyte-Derived Relaxing Factor; BK_{Ca}: Large Conductance Ca²⁺-activated K⁺ channels; cGMP: Cyclic Guanosine Monophosphate; CSE: Cystathionine γ-lyase; ECs: Endothelial Cells; EDHF: Endothelium-Derived Hyperpolarizing Factor; eNOS: Endothelial Nitric Oxide Synthase; HEK: Human Embryonic Kidney; HUVECs: Human Umbilical Vein Endothelial Cells; IK_{Ca}/SK_{Ca}: Intermediate and Small Conductance Ca²⁺-activated K⁺ channels; K_{ATP}: ATP Sensitive K⁺ channels; K_{Ca}: Ca²⁺-activated K⁺ channels; K_v: Voltage-gated K⁺ Channels; NO: Nitric Oxide; NOX-1: NADPH oxidase 1; O⁻: superoxide; PDE: Phosphodiesterase; PLA2: Phospholipase A2; VSMCs: Vascular Smooth Muscle Cells

Introduction

Hydrogen sulfide (H₂S) is colorless, water soluble, flammable gas with a strong smell that dissociates into H⁺, HS⁻, and S²⁻. H₂S is an endogenous signaling molecule also known as a gasotransmitter. Recent studies have indicated that H₂S has several important effects on cardioprotection, hepatoprotection, ion channels, protein modifications, mitochondrial metabolism, oxidative stress, and anti-apoptotic nature [1]. H₂S is produced endogenously by both enzymatic and non-enzymatic pathways [2]. In mammalian tissues, H₂S is mostly synthesized from L-cysteine by three enzymes:

Cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3-MST) [3]. In the vasculature, H₂S is produced in both the vascular endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) by CSE [2,4-7]. CSE is a pyridoxal 5'-phosphate-dependent cytosolic enzyme and CSE activity is regulated by intracellular Ca²⁺ concentrations [8]. H₂S is synthesized by CSE in several different reactions:

1. Cysteine + H₂O → pyruvate + H₂S + NH₃,
2. homocysteine → α-ketobutyrate + H₂S + NH₃,
3. homocysteine + homocysteine → homolanthionine + H₂S,
4. Cysteine + homocysteine → cystathionine + H₂S [9,10].

3-MST, along with cysteine aminotransferase (CAT) or D-amino acid oxidase (DAO), produces H₂S from cysteine and α-ketoglutarate in the mitochondria [11,12]. 3-MST/CAT is localized in thoracic aorta ECs and produces H₂S [13]; however, a vascular effect of 3-MST/CAT-derived H₂S is unknown. Endogenous intra mitochondrial 3-MST-derived H₂S has been shown to protect mitochondrial function/metabolism [14].

Compared to the understanding of H₂S biosynthesis, H₂S metabolism is poorly understood. H₂S is enzymatically metabolized by H₂S oxidation pathways in mitochondria:

1. H₂S → oxidized by sulfide quinone oxidoreductase → persulfide,
2. Persulfide → further oxidized by sulfur dioxygenase → sulfite (H₂SO₃),
3. H₂SO₃ → metabolized by rhodanese → thiosulfate (H₂S₂O₃) → excretion (kidneys) [15].

Other known pathways of H₂S metabolism are:

- Methylation by S-methyltransferase to methanethiol and dimethylsulfide in cytosol [16]
- Scavenged by oxyhemoglobin, methomoglobin, and metallo- or disulfide-containing molecules [2,16-18].

While the physiological effects of H₂S in the vasculature have been studied for almost two decades, and its vasoactive properties and effects on cellular proliferation and vascular remodeling are known,

***Corresponding author:** Beyer AM, Department of Medicine and Cardiovascular Center, Medical College of Wisconsin, Wisconsin, USA, Tel: 4144567514; E-mail: abeyer@mcw.edu

Received: February 03, 2015; **Accepted:** March 25, 2015; **Published:** March 31, 2015

Citation: Nishijima Y, Beyer AM (2015) H₂S in the Vasculature: Controversy of Mechanisms in Physiology, Pathology and Beyond. *Cardiol Pharmacol* 4: 135. doi:[10.4172/2329-6607.1000135](https://doi.org/10.4172/2329-6607.1000135)

Copyright: © 2015 Nishijima Y et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

the intracellular signaling pathways of H₂S are not yet determined. Similarly there is a disagreement as to whether H₂S contributes to the development of atherosclerosis, is vasoprotective, or possibly both. This review paper summarizes the effects of H₂S in the vascular system under physiological and pathological conditions. It also highlights the possible mechanisms involved with how H₂S signaling may contribute to the development of cardiovascular diseases. Figure 1 summarizes and gives an overview of the complex signaling events related to H₂S in the vasculature endothelium and smooth muscle cells.

H₂S in the Vasculature

The following section summarizes the numerous effects of H₂S on the vasculature and highlights some of the contributing factors.


H₂S induces both vasoconstriction and vasorelaxation. An increasing number of reports show that contribution of H₂S depends on vascular beds tested (e.g., aorta vs. mesenteric artery), vessel size (conduit vs. resistant) [5], endothelium (intact vs. denuded), gender [19], duration, concentration, and rate of administration of H₂S or its donor (e.g., NaHS). Other factors influencing H₂S response in the vasculature are model organisms and the precontraction methods (e.g., phenylephrine, U46619) [20,21]. It is established that H₂S induces a biphasic vascular response as lower doses tend to be vasoconstrictors, while higher doses are generally speaking vasodilators. For example, the H₂S donor NaHS at a lower concentration (< 100 μM) induces vasoconstriction but at a higher concentration (>100 μM), is a vasodilator in isolated rat mesenteric arteries [21]. Table 1 gives a

summary of the established vasoactive mechanisms of H₂S in human, swine, rodent, and cultured cells.

The mechanism of H₂S-induced vasoconstriction seems to mainly be inactivation of NO [22,23], inhibition of endothelial nitric oxide synthase (eNOS) activity/NO production [24-26], and down regulation of cAMP [27]. Mechanisms of H₂S-induced vasodilation consist of several complex pathways, including regulation of various ion channels, reduction of intracellular pH in SMCs [28], increase in cAMP production [29], and increase in cGMP by inhibition of phosphodiesterase (PDE) [30]. Furthermore, H₂S has been shown to act as an adipocyte-derived relaxing factor (ADRF) [10], and as an endothelium-derived hyperpolarizing factor (EDHF) [19]. Although the mechanisms of H₂S-induced vasodilation need to be explored further, its known functions suggest a significant role in a number of mechanism that contribute to the development of cardiovascular disease (CVD) therefore making it an attractive clinical target. To further the understanding of how H₂S contributes to the development of cardiovascular disease, it will be of critical importance to determine the effective doses in physiological and pathological circumstances.

Cellular Proliferation, Vascular Remodeling and Atherosclerosis

Since H₂S has similar physiological effects as NO increasing cardiovascular protective effects have been published. While both NO and H₂S have been shown to be vasodilators their mechanisms of action differ significantly. Unlike NO, which signals via the cGMP pathway,



Species	Vascular bed	Mechanism	Physiological effect	Reference
Human	Internal mammary artery	Vasoconstriction: ↓NO Vasodilation: ↑Opening of K _{ATP}	Biphasic vasoactive effect (constriction at lower dose, relaxation at higher dose)	[63]
	VSMCs	↑cAMP level by ↓O ₂ formation through NOX-1 expression and Rac1 activity	Vasorelaxation	[29]
	HUVECs	↑eNOS	Vasorelaxation	[59]
	HEK-293 cells	Opening K _{ATP} by S-sulfhydration at extracellular cysteine residues (C6 and C26) of SUR1 subunit	Membrane hyperpolarization	[64]
Bovine	Arterial ECs	↑Enos, ↑NO	Vasorelaxation	[60]
Swine	Cerebral artery	↑Opening of BK _{Ca}	Vasorelaxation	[65]
Rat	Aorta	Vasoconstriction: ↓eNOS Vasodilation: ↑Opening of K _{ATP} EC- dependent	Biphasic vasoactive effect (constriction at lower dose, relaxation at higher dose)	[23,24]
		Vasoconstriction: ↓NO by HCO ₃ ⁻	Biphasic vasoactive effect (constriction at lower dose, relaxation at higher dose)	[26]
		↓cAMP level	Vasoconstriction at low dose	[27]
		↑cGMP level by ↓PDE	Vasorelaxation	[30]
	Aorta and mesenteric artery	EC ₅₀ of H ₂ S, 125 ± 14 μM in aorta vs. 25 ± 3 μM in mesenteric artery	Vasorelaxation: Resistance vessels > Conduit vessels	[5]
		↑Opening of K _{ATP}	Vasorelaxation/hyperpolarization	[5,7,66]
	Coronary artery	↑Opening of K _v	Vasorelaxation	[67]
	<i>In vitro</i> (aorta) and <i>in vivo</i>	↓NO production, eNOS activity, L- Arginine uptake and transport	Downregulate L- Arginine/eNOS/NO pathway	[25]
	Mesenteric artery	Vasoconstriction: ↑AA release by ↑PLA2 Vasodilation: by cytochrome P450- derived metabolites	Biphasic vasoactive effect (constriction at lower dose, relaxation at higher dose)	[20]
		↑Opening of IK _{Ca} /SK _{Ca}	Vasorelaxation	[5,20]
Mesenteric artery/VSMCs	↑Opening of BK _{Ca} , EC-dependent	Vasorelaxation	[68,69]	
VSMCs (aorta)	↑CSE expression by NO	Vasorelaxation	[7]	
	↓intracellular pH via ↑Cl ⁻ /HCO ₃ ⁻ exchanger	Vasorelaxation	[28]	
Mouse	Aorta	Vasoconstriction: ↓eNOS	Biphasic vasoactive effect (constriction at lower dose, relaxation at higher dose)	[24]
	Coronary artery	↑Opening of BK _{Ca} and K _v , ↓Sheer stress mediated dilation	Vasorelaxation	[61]
	Mesenteric artery	↑Opening of K _{ATP}	Vasorelaxation	[70]
		↑Opening of IK _{Ca} /SK _{Ca} , EDHF	Vasorelaxation	[19,70]
	Mesenteric artery/SMCs	↑Opening of K _v (KCNQ) by perivascular adipose tissue derived-H ₂ S (as an ADRF)	Vasorelaxation	[10,71]
VSMCs (aorta)	Hyperpolarization in females but not males	Gender difference in membrane hyperpolarization	[19]	

Table 1: Physiological Effects of H₂S in Different Vascular Beds and Species.

H₂S is believed to activate a host of different ion channels directly. Researchers are not clear how the vessel-relaxing responsibilities are shared between NO and H₂S. Some evidence suggests that NO contributes mainly to conduit vessel-relaxation, while H₂S appears to work mainly in smaller blood vessels [31]. While the signaling properties under physiological conditions are being slowly uncovered, actions under pathological conditions are less defined. H₂S has previously been described to contribute to angiogenesis [32], collateral growth [33], and vascular proliferation [34]. Under pathological conditions, these same signaling events can lead to the development of atherosclerosis, a key factor in the development of CVD. Unregulated cellular proliferation and other shared signaling cascades contribute to the inward remodeling of the vasculature, one of the hallmarks of atherosclerosis. The exact mechanism of how H₂S contributes to this process remains elusive. While the major source of H₂S in plasma is likely produced by VSMCs [35], ECs have been recognized to contribute to the vascular effects stimulated by H₂S [36]. This divergence could contribute to the biphasic phenotypes observed with H₂S in vascular signaling (proliferative/antigenic nature vs. atheroprotective nature).

One of the major contributors to the development of vascular abnormalities is defects in mitochondrial oxidative phosphorylation and mitochondrial reactive oxygen species (ROS) production. In fact, the major EDHF in response to flow stimulus in subjects with coronary artery disease (CAD) is mitochondria-derived H₂O₂ [37], [38]. Mitochondria are the major energy factories of most cells, where ATP is produced via oxidative phosphorylation. Increased production of ROS in mitochondria (mt), alongside accumulation of mtDNA damage and progressive defects in respiratory chain function, are fundamentally linked to a broad number of cardiovascular diseases (CVD). Recently, H₂S has emerged as a key regulator of mitochondrial energy production. For example, a significant reduction of energy demand by H₂S has been established [39], and like nitric oxide, H₂S results in mitochondrial protection and reduced ROS production [40].

In isolated mouse cardiac mitochondria, the H₂S donor Na₂S improves posthypoxic mitochondrial respiration rate and restores mitochondrial function after 30 min of hypoxia [41]. Furthermore, H₂S has been shown to suppress H₂O₂ induced cellular senescence [42]. As mitochondrial ROS has quickly become one of the phenotypic

hallmarks of cardiovascular diseases, the exact regulatory system is not well defined. We have learned from several genetic disorders (e.g., Ataxia-Telangiectasia, Down Syndrome, Fanconi Anemia and Werner Syndrome) that mitochondrial dysfunction is a significant contributor to the development of cardiovascular phenotypes in these genetic diseases (reviewed by [43]). Similar to H₂S, the catalytic subunit of telomerase (TERT), a nuclear enzyme crucial for telomere maintenance, has been shown to have mitochondrial protective properties. Telomerase is an established regulator of cellular senescence and tissue aging. TERT has been shown to co-localize with the mitochondria where it also suppresses mtROS formation under stress conditions [44-46]. TERT, like H₂S, is increased in VSMC proliferation but also shows protective effects in other cells types, including the endothelium [46-49]. As increasing evidence show overlapping cellular phenotypes and interaction with similar signaling pathways (e.g., tyrosine kinase signaling [50,51], MAP kinases [52,53]), more detailed investigation of their connection is warranted in order to define these complex interactions.

Physiology vs. Pathophysiology

As part of the gas transmitter family of signaling molecules, the field of H₂S physiology has grown rapidly over the last decade. Interactions of H₂S and other gasotransmitters, sulfuring modification of proteins and the functional role of H₂S in multiple systems has shed light on its important role in the vasculature. Both preclinical and human studies have shown that disturbed synthesis of H₂S could contribute to pathologies of cardiovascular diseases. The definitions of physiological and super physiological, aka pathological, levels of H₂S are controversial. Physiological levels of H₂S in the vasculature seem to vary with methods of measurements, tissues, and species. Whiteman and Moore summarized that endogenous level of H₂S in plasma or serum is between 23-60 μM in rodents and adult humans [54]. Polmemus and Lefer concluded that blood concentration of H₂S is high nM to low μM and half-life (*in vivo*) is seconds to minutes [55]. Novel methods to measure steady-state and fluctuating levels of H₂S are needed to define a clear range of protective/positive effects on the vasculature and other organs.

While H₂S acts as a physiologically significant vasodilator, vasoconstrictor properties have also been identified and described. For example, H₂S has clear inhibitory effects on eNOS and produces a contractile response in the mouse aorta. H₂S also causes impairment of acetylcholine-mediated dilation likely via its direct inhibitory effect on eNOS [56]. Similarly, Zhao and colleagues showed that H₂S-induced vasorelaxation is attenuated by removal of the endothelium as well as NOS inhibition by L-NAME [57]. Furthermore, H₂S pretreatment blunted the effect of the NO donor, sodium nitroprusside. A more detailed overview of the overall effects of H₂S in health and disease is reviewed elsewhere [58].

While the role of H₂S in the pathogenesis of hypertension and vascular abnormalities is well documented [54,55], including regulation of the renin angiotensin system [24], the opposite question of how the physiological effects of H₂S are regulated under pathological conditions is less known. Increasing evidence is demonstrating that inhibitors of H₂S production or external H₂S donors have significant effects in various animal models of inflammation, reperfusion injury and circulatory shock [21]. The effects in human vessels or basic disease models and its underlying signaling properties, however, lag behind. Figure 2a shows that in isolated microvessels from subjects with coronary artery disease, the vasodilator response to H₂S is markedly reduced, underlining a need for further study in human tissue and subjects. As studies in


human vasculature are significantly more involved and restricted than animal studies future investigations of mechanism should go hand in hand. We need to use findings in the human vasculature to guide mechanistic studies in rodent and other preclinical studies. Using the well-established rat model of salt sensitive hypertension, we have observed a significant difference in the magnitude of H₂S-induced dilation compared to normal controls as illustrated in Figure 2b. H₂S-induced vasodilation in cerebral vessels from normal Sprague Dawley (SD) rats was eliminated by a high salt (HS) diet (3 days 4% NaCl). High salt diet is known to lower circulating angiotensin II (ANG II) signaling and with that significantly contributes to vascular, renal and other forms of hypertension. To our surprise in Dahl salt sensitive (SS) rats, a known model of chronically low plasma renin activity and low levels of circulating ANG II, vasodilation to H₂S was preserved even after treatment with HS diet. These findings suggest that an acute increase in salt load can block H₂S induced vasodilation by reducing the activity of the renin angiotensin system under physiological conditions. One potential mechanism of action could be the well-established effects of cAMP on renin expression [22] and signaling by the vascular renin-angiotensin system, as H₂S is also known to be a regulator of cAMP homeostasis [22]. In the SS models of salt sensitive low renin (and low ANG II) hypertension, H₂S-mediated vasodilation is preserved, suggesting an alternative pathway mediating the effects of H₂S in the vasculature as the effects of lowered cAMP no longer have physiological consequences via the renin angiotensin system.

While it is known that H₂S signaling overlaps with NO signaling, the details of these interactions are still being investigated. For example, NO donors upregulate the expression of CSE in cultured rat aortic SMCs in a concentration-dependent manner, suggesting NO increases the production of H₂S [7]. In line with these findings, our data presented in Figure 2c shows that inhibition of NOS with L-NAME in SS rats and healthy SD rats increases sensitivity to H₂S (one would expect this with a decrease in CSE expression due to decreased NO levels). The effects of H₂S on NO are somewhat controversial. NaHS or Na₂S increases NO production/eNOS phosphorylation at Ser-1177 in cultured endothelial cells [59,60], while, NaHS or Na₂S inhibits eNOS activity *in vivo* [61,62] and *in vitro* [25]. Additional studies are necessary to completely untangle this complicated signaling network.

Together these concepts suggest that different signaling events govern the effect of H₂S on the vasculature under so-called physiological conditions and acute stress responses vs. prolonged systemic exposure to external stressors (in this case salt load). Whether H₂S as a vasodilator is critical during acute changes of vascular environment (e.g., circulating factors, ROS, EDHF production) or as an activation of endogenous defense systems under chronic conditions remains to be determined.

Short Summary and Concluding Remarks

The recent progress made to understand the contribution of H₂S in the vasculature has been significant. Increasing evidence suggests physiological roles of this gasotransmitter in control of vascular reactivity with both contractile and dilator properties. The role of H₂S in pathophysiological hypertension, heart disease and inflammation is now well-accepted. Development of H₂S drugs is progressing and some clinical studies have been published (clinicaltrials.gov). Genetic models (e.g., CSE knockout mouse) have been generated and should contribute to the understanding of the physiological implication of this novel signaling molecule. However, despite this significant increase in our understanding of H₂S and its role in the vasculature, its relevance on the organism level (e.g., blood pressure control) is still



Human microvessels or rat middle cerebral vessels (MCA) were isolated from fresh tissue and cannulated onto glass pipettes of equal impedance as published previously [72,73]. After precontraction (human= ET-1; rat= myogenic tone), dilation to increasing amounts of the H₂S donor NaHS were performed. A) In human microvessels from individuals with no clinical diagnoses of coronary artery disease (CAD), a solid dilation to increasing doses of NaHS was observed, whereas in subjects with CAD, dilation was significantly decreased. B) In "healthy" SD rats with high salt diet (SD HS; 4% NaCl for 3 Days) eliminated H₂S mediated dilation. Inhibition of NOS (L-NAME 10⁻⁴ M) enhanced dilation at higher doses and blocked negative effect of the HS diet. C) In a model of salt sensitive (SS) hypertension, HS diet had no negative impact on dilation, but NOS blockage still increased H₂S response. * P<0.05 one way ANOVA vs low salt (LS) n=4-9; # P<0.05 vs non CAD control n=4-6.

Figure 2: Differential effect of H₂S in microvasculature.

poorly defined. For example, effective doses used for *ex-vivo* studies of vascular reactivity are several log units higher than those observed in the plasma. The question arises is circulating or tissue H₂S a poor marker of physiological ranges of this gas; and is the effective amounts observed *in vivo* significantly lower than concentrations needed for *ex vivo* or *in vitro* studies? Supporting this theory is the hypothesis that H₂S in plasma may simply be the spillover from its site of synthesis, and hence dose not correlate with cellular relevant doses. Hence we need to carefully consider measuring H₂S concentrations in cell/tissue and correlate these with concentrations where it contributes to physiological changes.

There are clearly many factors contributing to the ongoing debate about physiological effects of H₂S in the vasculature, its site of action, its transport, and its effects on other signaling pathways (e.g., NO). This article attempts to give a brief overview of some of the critical knowledge concerning H₂S in the vasculature. The somewhat unique feature of this gas is that it can serve as a vasodilator and a vasoconstrictor, based on the site and concentration. It would appear that cells exposed to toxic H₂S concentrations can adjust by altering their cellular environment (e.g., changes in gene expression, ROS and ATP production, and states of ion channels). The resulting effects of H₂S on the organ or even the entire animal (including humans) is dependent on the balance of its own signaling and other parameters that work in parallel or opposition of H₂S. These changes will likely result in alteration of H₂S concentrations as well at its rate of production and/or those of other signaling molecules. As the other gasotransmitters NO and CO arguably work in a similar way, the preexisting knowledge of these two ancestors should guide future studies to further the understanding of H₂S physiology.

Acknowledgment

This work was supported by National Institutes of Health Grant R21-OD-018306 (to A. M. Beyer)

Disclosures

No conflicts of interest, financial or otherwise, are declared by the author(s)

References

- King AL, Lefer DJ (2011) Cytoprotective actions of hydrogen sulfide in ischaemia-reperfusion injury. *Exp Physiol* 96: 840-846.
- Wang R (2002) Two's company, three's a crowd: can H₂S be the third endogenous gaseous transmitter? *Faseb j* 16: 1792-1798.
- Wang R (2012) Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. *Physiol Rev* 92: 791-896.
- Yang G, Wu L, Jiang B, Yang W, Qi J, et al. (2008) H₂S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. *Science* 322: 587-90.
- Cheng Y, Ndisang JF, Tang G, Cao K, Wang R, et al. (2004) Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. *Am J Physiol Heart Circ Physiol* 287: 2316-2323.
- Wang R (2003) The gasotransmitter role of hydrogen sulfide. *Antioxid Redox Signal* 5: 493-501.
- Zhao W, Jing Zhang, Yanjie Lu, Rui Wang (2011) The vasorelaxant effect of H₂S as a novel endogenous gaseous K(ATP) channel opener. *Embo j* 20: 6008-6016.
- Mikami Y, Shibuya N, Ogasawara Y, Kimura H (2013) Hydrogen sulfide is produced by cystathionine γ-lyase at the steady-state low intracellular Ca(2+) concentrations. *Biochem Biophys Res Commun* 431: 131-135.
- Kimura H (2014) Production and physiological effects of hydrogen sulfide. *Antioxid Redox Signal* 20: 783-793.
- BeĀtowski J (2013) Endogenous hydrogen sulfide in perivascular adipose tissue: role in the regulation of vascular tone in physiology and pathology. *Can J Physiol Pharmacol* 91: 889-898.
- Shibuya N, Tanaka M, Yoshida M, Ogasawara Y, Togawa T, et al. (2009) 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. *Antioxid Redox Signal* 11: 703-714.
- Shibuya N, Koike S, Tanaka M, Ishigami-Yuasa M, Kimura Y, et al. (2013) A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells. *Nat Commun* 4: 1366.

13. Shibuya N, Mikami Y, Kimura Y, Nagahara N, Kimura H (2009) Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. *J Biochem* 146: 623-626.
14. Modis K, Coletta C, Erdélyi K, Papapetropoulos A, Szabo C (2013) Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics. *Faseb j* 27: 601-611.
15. Kimura H (2014) Hydrogen sulfide and polysulfides as biological mediators. *Molecules* 19: 16146-16157.
16. Furne J, Springfield J, Koenig T, DeMaster E, Levitt MD (2001) Oxidation of hydrogen sulfide and methanethiol to thiosulfate by rat tissues: a specialized function of the colonic mucosa. *Biochem Pharmacol* 62: 255-259.
17. Beauchamp RO Jr, Bus JS, Popp JA, Boreiko CJ, Andjelkovich DA (1984) A critical review of the literature on hydrogen sulfide toxicity. *Crit Rev Toxicol* 13: 25-97.
18. Smith RP, Abbanat RA (1966) Protective effect of oxidized glutathione in acute sulfide poisoning. *Toxicol Appl Pharmacol* 9: 209-217.
19. Tang G, Yang G, Jiang B, Ju Y, Wu L, et al. (2013) H₂S is an endothelium-derived hyperpolarizing factor. *Antioxid Redox Signal* 19: 1634-1646.
20. d'Emmanuele di Villa Bianca R1, Sorrentino R, Coletta C, Mitidieri E, Rossi A, et al. (2011) Hydrogen sulfide-induced dual vascular effect involves arachidonic acid cascade in rat mesenteric arterial bed. *J Pharmacol Exp Ther* 337: 59-64.
21. Liu YH, Lu M, Hu LF, Wong PT, Webb GD, et al. (2012) Hydrogen sulfide in the mammalian cardiovascular system. *Antioxid Redox Signal* 17: 141-185.
22. Zhao W, Wang R (2002) H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. *Am J Physiol Heart Circ Physiol* 283: H474-480.
23. Ali MY, Ping CY, Mok YY, Ling L, Whiteman M, et al. (2006) Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? *Br J Pharmacol* 149: 625-634.
24. Kubo S, Doe I, Kurokawa Y, Nishikawa H, Kawabata A (2007) Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of vascular tension. *Toxicology* 232: 138-146.
25. Geng B, Cui Y, Zhao J, Yu F, Zhu Y, et al. (2007) Hydrogen sulfide downregulates the aortic L-arginine/nitric oxide pathway in rats. *Am J Physiol Regul Integr Comp Physiol* 293: R1608-1618.
26. Liu YH, Bian JS (2010) Bicarbonate-dependent effect of hydrogen sulfide on vascular contractility in rat aortic rings. *Am J Physiol Cell Physiol* 299: C866-872.
27. Lim JJ, Liu YH, Khin ES, Bian JS (2008) Vasoconstrictive effect of hydrogen sulfide involves downregulation of cAMP in vascular smooth muscle cells. *Am J Physiol Cell Physiol* 295: C1261-1270.
28. Lee SW, Cheng Y, Moore PK, Bian JS (2007) Hydrogen sulphide regulates intracellular pH in vascular smooth muscle cells. *Biochem Biophys Res Commun* 358: 1142-1147.
29. Muzaffar S, Shukla N, Bond M, Newby AC, Angelini GD, et al. (2008) Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 expression and Rac1 activity in human vascular smooth muscle cells. *J Vasc Res* 45: 521-528.
30. Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, et al. (2010) Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. *Arterioscler Thromb Vasc Biol* 30: 1998-2004.
31. Wang R (2010) Toxic gas, lifesaver. *Sci Am* 302: 66-71.
32. Papapetropoulos A1, Pyriochou A, Altaany Z, Yang G, Marazioti A, et al. (2009) Hydrogen sulfide is an endogenous stimulator of angiogenesis. *Proc Natl Acad Sci USA* 106: 21972-21977.
33. Wang MJ, Cai WJ, Li N, Ding YJ, Chen Y, et al. (2010) The hydrogen sulfide donor NaHS promotes angiogenesis in a rat model of hind limb ischemia. *Antioxid Redox Signal* 12: 1065-1077.
34. Du J, Hui Y, Cheung Y, Bin G, Jiang H, et al. (2004) The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. *Heart Vessels* 19: 75-80.
35. Zhao W, Zhang J, Lu Y, Wang R (2001) The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. *EMBO J* 20: 6008-6016.
36. Cheng Y, Ndisang JF, Tang G, Cao K, Wang R (2004) Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. *Am J Physiol Heart Circ Physiol* 287: H2316-2323.
37. Phillips SA, Hatoum OA, Gutterman DD (2007) The mechanism of flow-induced dilation in human adipose arterioles involves hydrogen peroxide during CAD. *Am J Physiol Heart Circ Physiol* 292: H93-100.
38. Freed JK, Beyer AM, LoGiudice JA, Hockenberry JC, Gutterman DD (2014) Ceramide changes the mediator of flow-induced vasodilation from nitric oxide to hydrogen peroxide in the human microcirculation. *Circ Res* 115: 525-532.
39. Blackstone E, Morrison M, Roth MB (2005) H₂S induces a suspended animation-like state in mice. *Science* 308: 518.
40. Kimura Y, Goto Y, Kimura H (2010) Hydrogen sulfide increases glutathione production and suppresses oxidative stress in mitochondria. *Antioxid Redox Signal* 12: 1-13.
41. Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, et al. (2007) Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. *Proc Natl Acad Sci U S A* 104: 15560-15565.
42. Suo R, Zhao ZZ, Tang ZH, Ren Z, Liu X, et al. (2013) Hydrogen sulfide prevents H₂O₂ induced senescence in human umbilical vein endothelial cells through SIRT1 activation. *Mol Med Rep* 7: 1865-1870.
43. Pallardó FV, Lloret A, Lebel M, d'Ischia M, Cogger VC, et al. (2010) Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. *Biogerontology* 11: 401-419.
44. Sharma NK, Reyes A, Green P, Caron MJ, Bonini MG, et al. (2012) Human telomerase acts as a hTR-independent reverse transcriptase in mitochondria. *Nucleic Acids Res* 40: 712-725.
45. Sahin E, Depinho RA (2010) Linking functional decline of telomeres, mitochondria and stem cells during ageing. *Nature* 464: 520-528.
46. Ahmed S, Passos JF, Birket MJ, Beckmann T, Brings S, et al. (2008) Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress. *J Cell Sci* 121: 1046-1053.
47. Zaccagnini G, Gaetano C, Della Pietra L, Nanni S, Grasselli A, et al. (2005) Telomerase mediates vascular endothelial growth factor-dependent responsiveness in a rat model of hind limb ischemia. *J Biol Chem* 280: 14790-14798.
48. Natarajan M, Mohan S, Konopinski R, Otto RA, Herman TS (2008) Induced telomerase activity in primary aortic endothelial cells by low-LET gamma-radiation is mediated through NF-kappaB activation. *Br J Radiol* 81: 711-720.
49. Kida I, Aoki M, Ogihara T, Rakugi H (2013) Anti-Apoptotic Effect of Human Telomerase Reverse Transcriptase on Endothelial Cells under Oxidative Stress, Independent of Telomere Elongation and Telomerase Activity. *Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry* 13: 112-121.
50. Denu JM, Tanner KG (1998) Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. *Biochemistry* 37: 5633-5642.
51. Kharbanda S, Kumar V, Dhar S, Pandey P, Chen C, et al. (2000) Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. *Curr Biol* 10: 568-575.
52. Janknecht R (2004) On the road to immortality: hTERT upregulation in cancer cells. *FEBS Lett* 564: 9-13.
53. Adhikari S, Bhatia M (2008) H₂S-induced pancreatic acinar cell apoptosis is mediated via JNK and p38 MAP kinase. *J Cell Mol Med* 12: 1374-1383.
54. Whiteman M, Moore PK (2009) Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? *J Cell Mol Med* 13: 488-507.
55. Polhemus DJ, Lefer DJ (2014) Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. *Circ Res* 114: 730-737.
56. Kubo S, Doe I, Kurokawa Y, Nishikawa H, Kawabata A (2007) Direct inhibition of endothelial nitric oxide synthase by hydrogen sulfide: contribution to dual modulation of vascular tension. *Toxicology* 232: 138-146.
57. Zhao W, Wang R (2002) H(2)S-induced vasorelaxation and underlying cellular and molecular mechanisms. *Am J Physiol Heart Circ Physiol* 283: H474-480.
58. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J (2011) Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. *Clinical Science* 121: 459-488.

59. Chen PH, Fu YS, Wang YM, Yang KH, Wang DL, et al. (2014) Hydrogen sulfide increases nitric oxide production and subsequent S-nitrosylation in endothelial cells. *ScientificWorldJournal* 2014: 480387.
60. Predmore BL, Julian D, Cardounel AJ (2011) Hydrogen sulfide increases nitric oxide production from endothelial cells by an akt-dependent mechanism. *Front Physiol* 2: 104.
61. Chai Q, Lu T, Wang XL, Lee HC (2015) Hydrogen sulfide impairs shear stress-induced vasodilation in mouse coronary arteries. *Pflugers Arch* 467: 329-340.
62. Kubo S, Kurokawa Y, Doe I, Masuko T, Sekiguchi F, et al. (2007) Hydrogen sulfide inhibits activity of three isoforms of recombinant nitric oxide synthase. *Toxicology* 241: 92-97.
63. Webb GD, Lim LH, Oh VM, Yeo SB, Cheong YP, et al. (2008) Contractile and vasorelaxant effects of hydrogen sulfide and its biosynthesis in the human internal mammary artery. *J Pharmacol Exp Ther* 324: 876-882.
64. Jiang B, Tang G, Cao K, Wu L, Wang R (2010) Molecular mechanism for H(2)S-induced activation of K(ATP) channels. *Antioxid Redox Signal* 12: 1167-1178.
65. Liang GH, Xi Q, Leffler CW, Jaggar JH (2012) Hydrogen sulfide activates Ca²⁺ sparks to induce cerebral arteriole dilatation. *J Physiol* 590: 2709-2720.
66. Tang G, Wu L, Liang W, Wang R (2005) Direct stimulation of K(ATP) channels by exogenous and endogenous hydrogen sulfide in vascular smooth muscle cells. *Mol Pharmacol* 68: 1757-1764.
67. Cheang WS, Wong WT, Shen B, Lau CW, Tian XY, et al. (2010) 4-aminopyridine-sensitive K⁺ channels contributes to NaHS-induced membrane hyperpolarization and relaxation in the rat coronary artery. *Vascul Pharmacol* 53: 94-98.
68. Jackson-Weaver O, Paredes DA, Gonzalez Bosc LV, Walker BR, Kanagy NL (2011) Intermittent hypoxia in rats increases myogenic tone through loss of hydrogen sulfide activation of large-conductance Ca(2+)-activated potassium channels. *Circ Res* 108: 1439-1447.
69. Jackson-Weaver O, Osmond JM, Riddle MA, Naik JS, Gonzalez Bosc LV, et al. (2013) Hydrogen sulfide dilates rat mesenteric arteries by activating endothelial large-conductance Ca²⁺-activated K⁺ channels and smooth muscle Ca²⁺ sparks. *Am J Physiol Heart Circ Physiol* 304: H1446-1454.
70. Mustafa AK, Sikka G, Gazi SK, Stepan J, Jung SM, et al. (2011) Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. *Circ Res* 109: 1259-1268.
71. Schleifenbaum J, Köhn C, Voblova N, Dubrovskaya G, Zavarinskaya O, et al. (2010) Systemic peripheral artery relaxation by KCNQ channel openers and hydrogen sulfide. *J Hypertens* 28: 1875-1882.
72. Beyer AM, Raffai G, Weinberg B, Fredrich K, Lombard JH (2012) Dahl salt-sensitive rats are protected against vascular defects related to diet-induced obesity. *Hypertension* 60: 404-410.
73. Beyer AM, Durand MJ, Hockenberry J, Gamblin TC, Phillips SA, et al. (2014) An acute rise in intraluminal pressure shifts the mediator of flow-mediated dilation from nitric oxide to hydrogen peroxide in human arterioles. *Am J Physiol Heart Circ Physiol* 307: H1587-1593.